Literature DB >> 8267111

A double-blind, placebo-controlled crossover study of ganglioside GM1 treatment for Alzheimer's disease.

C Flicker1, S H Ferris, D Kalkstein, M Serby.   

Abstract

In a double-blind trial, 12 patients with probable Alzheimer's disease were treated for 6 weeks with placebo and 6 weeks with monosialoganglioside (GM1) (100 mg/day i.m.), which potentiates the actions of nerve growth factor. GM1 failed to produce significant improvement in patients' cognitive test performance, suggesting that this is not a viable approach to the treatment of cognitive deterioration in Alzheimer's disease.

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 8267111     DOI： 10.1176/ajp.151.1.126

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN： 0002-953X            Impact factor:   18.112


  8 in total

Review 1.  Memory deficits in Alzheimer's disease: the encoding hypothesis and cholinergic function.

Authors:  K Geoffrey White; Angela C Ruske
Journal:  Psychon Bull Rev       Date:  2002-09

Review 2.  Galanin-acetylcholine interactions in rodent memory tasks and Alzheimer's disease.

Authors:  M P McDonald; J N Crawley
Journal:  J Psychiatry Neurosci       Date:  1997-11       Impact factor: 6.186

3.  The Neuroprotective Effect of GM-1 Ganglioside on the Amyloid-Beta-Induced Oxidative Stress in PC-12 Cells Mediated by Nrf-2/ARE Signaling Pathway.

Authors:  Xiaonan Wang; Bei Li; Xiaohong Yu; Ye Zhou; Yue Gao
Journal:  Neurochem Res       Date:  2022-05-30       Impact factor: 4.414

Review 4.  Amyloid beta-protein assembly as a therapeutic target of Alzheimer's disease.

Authors:  Ghiam Yamin; Kenjiro Ono; Mohammed Inayathullah; David B Teplow
Journal:  Curr Pharm Des       Date:  2008       Impact factor: 3.116

Review 5.  The Pathogenic Role of Ganglioside Metabolism in Alzheimer's Disease-Cholinergic Neuron-Specific Gangliosides and Neurogenesis.

Authors:  Toshio Ariga
Journal:  Mol Neurobiol       Date:  2017-01       Impact factor: 5.590

Review 6.  Advances in the pharmacotherapy of Alzheimer's disease.

Authors:  J C Soares; S Gershon
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1994       Impact factor: 5.270

Review 7.  Gangliosides: Treatment Avenues in Neurodegenerative Disease.

Authors:  Pierre J Magistretti; Fred H Geisler; Jay S Schneider; P Andy Li; Hubert Fiumelli; Simonetta Sipione
Journal:  Front Neurol       Date:  2019-08-06       Impact factor: 4.003

8.  Intracerebroventricular Infusion of Gangliosides Augments the Adult Neural Stem Cell Pool in Mouse Brain.

Authors:  Yutaka Itokazu; Dongpei Li; Robert K Yu
Journal:  ASN Neuro       Date:  2019 Jan-Dec       Impact factor: 4.146
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.